Fusion Antibodies plc (AIM:FAB)
London · Delayed Price · Currency is GBP · Price in GBX 11.51
-0.49 (-4.08%)
Sep 25, 2026, 2:12 PM GMT
Fusion Antibodies Revenue
In the fiscal year ending March 31, 2026, Fusion Antibodies had annual revenue of 2.11M GBP with 7.38% growth. Fusion Antibodies had revenue of 1.27M in the half year ending March 31, 2026, with 113.78% growth.
Revenue
2.11M
Revenue Growth
+7.38%
P/S Ratio
7.12
Revenue / Employee
78.15K
Employees
27
Market Cap
15.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.11M | 145.00K | 7.38% |
| Mar 31, 2025 | 1.97M | 829.00K | 72.98% |
| Mar 31, 2024 | 1.14M | -1.77M | -60.84% |
| Mar 31, 2023 | 2.90M | -1.90M | -39.55% |
| Mar 31, 2022 | 4.80M | 634.00K | 15.22% |
| Mar 31, 2021 | 4.17M | 270.00K | 6.93% |
| Mar 31, 2020 | 3.90M | 1.71M | 78.51% |
| Mar 31, 2019 | 2.18M | -508.74K | -18.91% |
| Mar 31, 2018 | 2.69M | 776.79K | 40.59% |
| Mar 31, 2017 | 1.91M | 432.69K | 29.21% |
| Mar 31, 2016 | 1.48M | 571.97K | 62.90% |
| Mar 31, 2015 | 909.29K | 186.25K | 25.76% |
| Mar 31, 2014 | 723.05K | 318.05K | 78.53% |
| Mar 31, 2013 | 405.00K | -87.30K | -17.73% |
| Mar 31, 2011 | 492.29K | 55.35K | 12.67% |
| Mar 31, 2010 | 436.95K | -24.11K | -5.23% |
| Mar 31, 2009 | 461.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 9.76M |
| IXICO | 7.28M |
| SkinBioTherapeutics | 5.23M |
| Aptamer Group | 1.38M |
| Oxford BioDynamics | 1.20M |
| Genflow Biosciences | 585.61K |
| CRISM Therapeutics | 352.00K |
| Solvonis Therapeutics | 31.87K |